Wave Life Sciences (WVE) Issues Earnings Results

Wave Life Sciences (NASDAQ:WVE) issued its quarterly earnings results on Friday. The company reported ($1.36) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.19) by ($0.17), MarketWatch Earnings reports. Wave Life Sciences had a negative return on equity of 136.64% and a negative net margin of 1,017.43%. The firm had revenue of $3.03 million for the quarter, compared to analyst estimates of $9.66 million.

Shares of WVE stock traded up $0.39 on Friday, hitting $27.70. The company had a trading volume of 280,312 shares, compared to its average volume of 701,856. The stock has a market cap of $935.52 million, a PE ratio of -5.47 and a beta of 0.56. The company has a quick ratio of 1.56, a current ratio of 1.56 and a debt-to-equity ratio of 0.13. Wave Life Sciences has a twelve month low of $22.90 and a twelve month high of $56.00.

In other news, insider Paul Bolno sold 50,000 shares of the business’s stock in a transaction dated Friday, March 15th. The stock was sold at an average price of $45.48, for a total value of $2,274,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Michael A. Panzara sold 7,000 shares of the business’s stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $48.00, for a total value of $336,000.00. The disclosure for this sale can be found here. Insiders own 44.20% of the company’s stock.

A number of analysts have commented on the company. BidaskClub raised Wave Life Sciences from a “sell” rating to a “hold” rating in a research report on Wednesday, April 10th. HC Wainwright reaffirmed a “buy” rating and set a $33.00 price target (down previously from $49.00) on shares of Wave Life Sciences in a research report on Wednesday, April 17th. ValuEngine cut Wave Life Sciences from a “strong-buy” rating to a “buy” rating in a research report on Monday, March 25th. Stifel Nicolaus cut Wave Life Sciences from a “buy” rating to a “hold” rating in a research report on Tuesday, April 16th. Finally, Zacks Investment Research cut Wave Life Sciences from a “hold” rating to a “sell” rating in a report on Saturday, March 9th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $53.75.

COPYRIGHT VIOLATION NOTICE: “Wave Life Sciences (WVE) Issues Earnings Results” was originally published by WKRB News and is owned by of WKRB News. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this report can be viewed at https://www.wkrb13.com/2019/05/11/wave-life-sciences-wve-issues-earnings-results.html.

About Wave Life Sciences

Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces of novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. The company is primarily developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.

Further Reading: Why do commodities matter?

Earnings History for Wave Life Sciences (NASDAQ:WVE)

Receive News & Ratings for Wave Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.